← Eichor
Condition: High Grade B Cell Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: High Grade B Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B C
Phase 1/Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06249191AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 7 location(s) · British Columbia Cancer Agency · NCT06208735Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Inter
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05801913Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
NA · 1 location(s) · Hua-Jay J Cherng, MD · NCT06693830CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Marcela V. Maus, M.D.,Ph.D. · NCT06026319A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06765317A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Ly
Phase 2 · 2 location(s) · University of California, Davis · NCT05600686CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 · 1 location(s) · Northside Hospital, Inc. · NCT05909059A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Pre
Phase 3 · 62 location(s) · Grifols Therapeutics LLC · NCT05645107Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Le
Phase 2 · 4 location(s) · Mayo Clinic · NCT03418038Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Ly
Phase N/A · 20 location(s) · Fondazione Italiana Linfomi - ETS · NCT06588205Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 2 · 77 location(s) · Allogene Therapeutics · NCT06500273R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
NA · 1 location(s) · oubai, MD/PhD · NCT05040555A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade
Phase 2 · 7 location(s) · Istituto Clinico Humanitas · NCT06918912HPC Offered for PRESERVE Expansion
Phase N/A · 4 location(s) · Ossium Health, Inc. · NCT07145411A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Ref
Phase 1 · 1 location(s) · GenomeFrontier Therapeutics TW Co., Ltd. · NCT06703892Immunotherapy in Lymphoma
Phase N/A · 2 location(s) · Sung-Soo Park · NCT06796517Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.